Pharmaceutical enterprises are many, small, scattered and disorganized problems are prominent, the lack of large-scale leading enterprises. The national pharmaceutical industry enterprises 3613, of which 423 large enterprises, accounting for only 11.7% of the total. Most enterprises are not highly specialized and lack their own brands and specialty varieties. Most enterprises are not only small in scale, poor production conditions, backward technology, obsolete equipment, low management level, and the layout of the dispersion of the enterprise's production concentration is far lower than the level of advanced countries. 2000, China's pharmaceutical industry sales of the largest 60 enterprises in the production concentration is 35.7%, while the world's top 20 pharmaceutical companies accounted for sales of the world's pharmaceutical market share of about 60%.
2. The enterprise-centered technological innovation system has not yet been formed.
The foundation of new drug innovation is weak, the mechanism of pharmaceutical technology innovation and rapid industrialization of scientific and technological achievements has not yet been fully formed, the pharmaceutical science and technology investment is insufficient, the lack of new products with China's independent intellectual property rights, the product is slow to update, and the duplication of serious. 97% of the varieties of chemical APIs are imitation products. More old products, fewer new products; low-grade and low value-added products, high technology content and high value-added products; duplication of production varieties, exclusive brand less. Some products such as gentamicin, paracetamol, vitamin B1, metronidazole and other preparations have dozens or even hundreds of enterprises. Even new products, repeat production phenomenon is also very serious, such as the second class of new drugs levofloxacin preparation there are 34 enterprises to produce, clarithromycin preparation there are 35 enterprises to produce.
The application of high-tech transformation of traditional industries at a slower pace. Most of the old products have low technical and economic indicators, backward technology, high cost and lack of international competitiveness.
3. Pharmaceutical distribution system is not yet sound.
Three wholesale pattern formed under the planned economic system is basically broken after the new effective pharmaceutical distribution system has not yet been fully formed, the illegal drug market is unchecked. Coupled with the production field for many years of low-level duplication of construction, resulting in most varieties of serious supply exceeds demand, the circulation order is chaotic, the management of the task is arduous. But now to jiuzhou tong, national pharmaceutical holdings, China resources and other leading pharmaceutical distribution enterprises in the large-scale mergers and acquisitions of commercial companies, in order to change the current situation of the pharmaceutical market.
4. Medical device product quality performance is poor.
China's own production of medical equipment products are mostly low value-added conventional medium and low-grade products, while the clinically required high-precision, sophisticated medical equipment and most of the new practical medical equipment need to be imported. Conventional medical equipment products are slow to update, low technology content, product quality can not meet the high quality requirements of health care, product repair rate and downtime rate is higher than similar products abroad, the reliability of the product is not stable.
5. Preparation varieties and varieties of APIs do not match.
China has been the international production of APIs in large countries, but not enough research on the development of drug preparation technology, preparation level is low, most of the preparation of low product quality, difficult to enter the international market; China's average of an API can only be made into three preparations, while a foreign API can be made into a dozen or even dozens of preparations; preparation technology is backward, the stability of the product quality of the preparations is not high.
6. Pharmaceutical products import and export structure is unreasonable.
China is still not out of the traditional export of low value-added, heavily polluted chemical raw materials and conventional surgical instruments, sanitary materials, Chinese herbal medicine, and imports of expensive preparations and large-scale, high-grade medical equipment import and export model, the proportion of exports of high-tech products is low.
Insufficient development of international markets, poor information channels, slow response to international market information. In particular, the lack of joint development of the international market consciousness and mechanism.